Analysts Issue Forecasts for ZNTL Q1 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.68) per share for the quarter. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.49) EPS and Q4 2025 earnings at ($0.42) EPS.

Other analysts have also issued research reports about the company. UBS Group lowered their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Wells Fargo & Company reduced their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. HC Wainwright decreased their price target on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Finally, Guggenheim reduced their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Trading Down 11.1 %

Shares of ZNTL opened at $1.92 on Friday. The firm has a market capitalization of $136.82 million, a P/E ratio of -0.77 and a beta of 1.82. Zentalis Pharmaceuticals has a 12-month low of $1.61 and a 12-month high of $18.07. The firm has a fifty day moving average price of $2.77 and a 200-day moving average price of $3.20.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Verition Fund Management LLC increased its position in shares of Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after purchasing an additional 951,500 shares during the last quarter. Primecap Management Co. CA boosted its holdings in shares of Zentalis Pharmaceuticals by 21.6% in the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after buying an additional 265,690 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after purchasing an additional 353,384 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Zentalis Pharmaceuticals by 22.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock valued at $1,507,000 after acquiring an additional 91,152 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 126.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after acquiring an additional 127,868 shares in the last quarter.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, Director Jan Skvarka bought 60,000 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the completion of the acquisition, the director now directly owns 149,551 shares of the company’s stock, valued at $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.60% of the company’s stock.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.